Capromab pendetide

Identification

Summary

Capromab pendetide is a monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.

Generic Name
Capromab pendetide
DrugBank Accession Number
DB00089
Background

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Db00089
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • (111In)-Capromab pendetide
  • Capromab pendetide
  • Indium (111In) capromab pendetide
  • Indium 111 Capromab Pendetide
  • Indium In 111 capromab pendetide
External IDs
  • CYT-356
  • Cytogen 356

Pharmacology

Indication

For diagnosis of prostate cancer and detection of intra-pelvic metastases.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.

Mechanism of action

Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.

TargetActionsOrganism
AGlutamate carboxypeptidase 2
other/unknown
Humans
Absorption

Not Available

Volume of distribution
  • 4 ± 2.1 L
Protein binding

Not Available

Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

Route of elimination

Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.

Half-life

Not Available

Clearance
  • 42 +/- 22 mL/hr
Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Capromab pendetide.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Capromab pendetide.
AducanumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Capromab pendetide.
AlirocumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Capromab pendetide is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
ProstaScint (Cytogen Corp.)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ProstaScint Kit for the Preparation of Indium In 111 Capromab PendetideKit0.5 mg/1mLIntravenousJazz Pharmaceuticals, Inc.1996-10-282015-05-22US flag

Categories

ATC Codes
V09IB04 — Indium (111in) capromab pendetide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
BDO5072GRX
CAS number
145464-28-4

References

General References
  1. Link [Link]
  2. Link [Link]
  3. Link [Link]
PubChem Substance
46506263
RxNav
136300
ChEMBL
CHEMBL2108285
Therapeutic Targets Database
DAP001049
PharmGKB
PA164745489
Wikipedia
Indium_(111In)_capromab_pendetide
FDA label
Download (1.65 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedDiagnosticProstate Cancer1
1CompletedDiagnosticProstate Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • EUSA Pharma Inc.
Dosage Forms
FormRouteStrength
KitIntravenous0.5 mg/1mL
Prices
Unit descriptionCostUnit
Prostascint kit1584.0USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Other/unknown
General Function
Tetrahydrofolyl-poly(glutamate) polymer binding
Specific Function
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of fola...
Gene Name
FOLH1
Uniprot ID
Q04609
Uniprot Name
Glutamate carboxypeptidase 2
Molecular Weight
84330.015 Da
References
  1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [Article]
  2. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [Article]
  3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [Article]
  4. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [Article]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created on June 13, 2005 13:24 / Updated on October 03, 2021 00:34